🚀 VC round data is live in beta, check it out!
Panion & Bf Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Panion & Bf Biotech and similar public comparables like ProQR Therapeutics, Biomm, Ryvu Therapeutics, Fate Therapeutics and more.
Panion & Bf Biotech Overview
About Panion & Bf Biotech
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company along with its subsidiaries is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan, China, Hong Kong, and Macau, the USA, and Korea. It generates a majority of its revenue from the Taiwan segment.
Founded
1976
HQ
Employees
398
Website
Financials (FY)
EV
$174M
Panion & Bf Biotech Financials
Panion & Bf Biotech reported last fiscal year revenue of $64M and EBITDA of $12M.
In the same fiscal year, Panion & Bf Biotech generated $34M in gross profit, $12M in EBITDA, and $4M in net income.
Revenue (LTM)
Panion & Bf Biotech P&L
In the most recent fiscal year, Panion & Bf Biotech reported revenue of $64M and EBITDA of $12M.
Panion & Bf Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $64M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $34M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA | — | XXX | $12M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 11% | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Margin | — | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Panion & Bf Biotech Stock Performance
Panion & Bf Biotech has current market cap of $166M, and enterprise value of $174M.
Market Cap Evolution
Panion & Bf Biotech's stock price is $1.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $174M | $166M | (0.9%) | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPanion & Bf Biotech Valuation Multiples
Panion & Bf Biotech trades at 2.7x EV/Revenue multiple, and 14.0x EV/EBITDA.
EV / Revenue (LTM)
Panion & Bf Biotech Financial Valuation Multiples
As of March 7, 2026, Panion & Bf Biotech has market cap of $166M and EV of $174M.
Equity research analysts estimate Panion & Bf Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Panion & Bf Biotech has a P/E ratio of 42.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV (current) | $174M | XXX | $174M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 25.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.2x | XXX | XXX | XXX |
| P/E | — | XXX | 42.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 33.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Panion & Bf Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Panion & Bf Biotech Margins & Growth Rates
Panion & Bf Biotech's revenue in the last fiscal year grew by 8%.
Panion & Bf Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 13% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Panion & Bf Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ProQR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomm | XXX | XXX | XXX | XXX | XXX | XXX |
| Ryvu Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kalaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Panion & Bf Biotech M&A Activity
Panion & Bf Biotech acquired XXX companies to date.
Last acquisition by Panion & Bf Biotech was on XXXXXXXX, XXXXX. Panion & Bf Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Panion & Bf Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPanion & Bf Biotech Investment Activity
Panion & Bf Biotech invested in XXX companies to date.
Panion & Bf Biotech made its latest investment on XXXXXXXX, XXXXX. Panion & Bf Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Panion & Bf Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Panion & Bf Biotech
| When was Panion & Bf Biotech founded? | Panion & Bf Biotech was founded in 1976. |
| Where is Panion & Bf Biotech headquartered? | Panion & Bf Biotech is headquartered in Taiwan. |
| How many employees does Panion & Bf Biotech have? | As of today, Panion & Bf Biotech has over 398 employees. |
| Is Panion & Bf Biotech publicly listed? | Yes, Panion & Bf Biotech is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Panion & Bf Biotech? | Panion & Bf Biotech trades under 1760 ticker. |
| When did Panion & Bf Biotech go public? | Panion & Bf Biotech went public in 2004. |
| Who are competitors of Panion & Bf Biotech? | Panion & Bf Biotech main competitors are ProQR Therapeutics, Biomm, Ryvu Therapeutics, Fate Therapeutics. |
| What is the current market cap of Panion & Bf Biotech? | Panion & Bf Biotech's current market cap is $166M. |
| What is the current revenue of Panion & Bf Biotech? | Panion & Bf Biotech's last fiscal year revenue is $64M. |
| What is the current EV/Revenue multiple of Panion & Bf Biotech? | Current revenue multiple of Panion & Bf Biotech is 2.7x. |
| Is Panion & Bf Biotech profitable? | No, Panion & Bf Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.